Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech
Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if…
March 16, 2018 - 2 minutes
Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if…
Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat…
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials…
For our first interview at the SACHS Conference in Basel yesterday, I met with François Conquet, founder…
Which part of our body do European biotechs prefer to target? And how diversified are…